The two major determinants of long-term survival after allongeneic marrow transplantation for acute lymphocytic leukemia (ALL) are the occurrence of cytomegalovirus (CMV) infection and recurrence (relapse) of leukemia. An ongoing study has investigated the safety and toxicity of human leukocyte interferon given after transplant for ALL in remission. Interferon has been shown to be safe when given as early as 2-3 weeks after transplant though, as expected, the circulating neutrophil counts of interferon recipients are lower than those of non-recipients. Between 20 and 80 days after transplant the natural killer (NK) actvity of cells taken from interferon recipients is higher than that of non-recipients and no further augmentation of NK activity occurs after exposure of these cells to interferon in vitro. Although the clinical effects of interferon given prohylactically can only be analyzed preliminarily, it appears that a lower relapse rate may be occurring among interferon recipients but no significant change in CMV infection. It is proposed to complete the present study of the prophylactic use of interferon and to extend it to patients with other types of leukemia; these patients will receive interferon beginning one week befere transplant and will also have the sensitivity of their leukemia cells to interferon examined in vitro before transplant. These latter data will later be compared to the duration of remission after transplant. Finally, the use of interferons alone and in combination with other antiviral agents will be examined in vitro for toxicity to marrow progenitor cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA026966-05
Application #
3167507
Study Section
Experimental Immunology Study Section (EI)
Project Start
1979-12-01
Project End
1988-11-30
Budget Start
1984-12-01
Budget End
1985-11-30
Support Year
5
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bowden, R A; Coombs, R W; Nikora, B H et al. (1990) Progression of human immunodeficiency virus type-1 infection after allogeneic marrow transplantation. Am J Med 88:49N-52N
Reusser, P; Fisher, L D; Buckner, C D et al. (1990) Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 75:1888-94
Reed, E C; Wolford, J L; Kopecky, K J et al. (1990) Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial. Ann Intern Med 112:505-10
Ljungman, P; Bowden, R A; Meyers, J D (1990) Cytotoxic activity against varicella-zoster virus-infected target cells after marrow transplantation. J Clin Lab Immunol 31:17-21
Gleaves, C A; Myerson, D; Bowden, R A et al. (1989) Direct detection of cytomegalovirus from bronchoalveolar lavage samples by using a rapid in situ DNA hybridization assay. J Clin Microbiol 27:2429-32
Meyers, J D; Bowden, R A; Counts, G W (1989) Infectious complications of marrow transplant: risk factors for infection. Prog Clin Biol Res 309:357-66
Meyers, J D (1989) Prevention of cytomegalovirus infection after marrow transplantation. Rev Infect Dis 11 Suppl 7:S1691-705
Meyers, J D (1988) Management of cytomegalovirus infection. Am J Med 85:102-6
Meyers, J D (1988) Prevention and treatment of cytomegalovirus infection after marrow transplantation. Bone Marrow Transplant 3:95-104
Bowden, R A; Dobbs, S; Kopecky, K J et al. (1988) Increased cytotoxicity against cytomegalovirus-infected target cells by bronchoalveolar lavage cells from bone marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 158:773-9

Showing the most recent 10 out of 16 publications